Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIA Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

Trial Profile

A Phase IIA Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs ASLAN 003 (Primary) ; Azacitidine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ASLAN Pharmaceuticals
  • Most Recent Events

    • 29 Jan 2019 According to an ASLAN Pharmaceuticals media release, the company expects to complete the first part of this study in the first half of 2019.
    • 09 Jan 2019 Planned number of patients changed from 38 to 56.
    • 09 Jan 2019 Planned End Date changed from 1 Dec 2019 to 31 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top